Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 16Lung Neoplasms 10Breast Neoplasms 10Uterine Cervical Neoplasms 9Lymphoma 8Squamous Cell Carcinoma of Head and Neck 7Prostatic Neoplasms 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Head and Neck Neoplasms 7Lymphoma, Large B-Cell, Diffuse 6Sarcoma 5Melanoma 5Lymphoma, Follicular 5Leukemia 5Colorectal Neoplasms 5Adenocarcinoma of Lung 5Small Cell Lung Carcinoma 4Rectal Neoplasms 4Lymphoma, Non-Hodgkin 4Lymphoma, Mantle-Cell 4Lymphoma, Large-Cell, Immunoblastic 4Lymphoma, B-Cell, Marginal Zone 4Leukemia, Myeloid, Acute 4Leukemia, Lymphocytic, Chronic, B-Cell 4Glioblastoma 4Central Nervous System Neoplasms 4Carcinoma, Hepatocellular 4Burkitt Lymphoma 4Ovarian Neoplasms 3Neoplasms 3

Interventions

transplatin 1pembrolizumab 1Radiotherapy 1Radiation Dose Hypofractionation 1Radiation 1Platinum 1Gemcitabine 1Cystectomy 1Cisplatin 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Infiltrating Bladder Urothelial Carcinoma × Radiotherapy × Clear all
NCT03419130 2018-12-07

Radiation Therapy and Pembrolizumab in Treating Patients With Localized Urothelial Bladder Cancer

University of California, San Francisco

Phase 2 Withdrawn
Genitourinary

Infiltrating Bladder Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡